Skip to content
All life stages
Life stage

Stroke recovery

Post-stroke rehabilitation and secondary prevention — the population where neurotrophic peptides have their strongest source-jurisdiction registered evidence, with cross-jurisdictional replication as the load-bearing methodological gap.

What changes during this transition

Stroke remains a leading cause of disability worldwide. Standard-of-care is acute reperfusion (tPA / thrombectomy within the eligible window), early multidisciplinary rehabilitation (PT, OT, SLP), and aggressive secondary prevention (statin, antiplatelet or anticoagulant, BP control, AFib management). Post-stroke depression and anxiety are common (~30% combined prevalence) and the FOCUS / AFFINITY / EFFECTS era of fluoxetine trials reshaped how SSRIs are used in recovery. Peptide relevance here is the most jurisdictionally heterogeneous axis in the library. Cerebrolysin is registered in 50+ countries with CASTA (Heiss 2012, n=1,070, missed primary endpoint but positive subgroup signal in NIHSS ≥12) and CARS-1 (Muresanu 2016, n=208, ARAT improvement in moderate-severe upper-limb hemiparesis) — Tier 2 in this library. Semax has Russian Ministry of Health approval (1994) for acute ischemic stroke; Gusev et al. 2018 and earlier Russian neurology cohorts back the registered indication — Tier 3. B12-methylcobalamin's case is two-fold: confirmed-deficiency repletion (established medicine) plus the homocysteine-lowering secondary-prevention story (mixed RCT evidence; VITATOPS negative, HOPE-2 positive subgroup). Selank addresses the post-stroke anxiety + benzo-sparing taper context, NOT direct stroke-recovery. Thymosin alpha-1 is substrate-only — narrow to ICU-complication subset (severe aspiration pneumonia / sepsis), NOT general outpatient recovery. Editorial frame: rehabilitation discipline outranks peptide selection by a wide margin. Cerebrolysin and semax both require clinic-supervised administration (IV/IM cycles or intranasal multiple times daily); neither is a take-home peptide-clinic decision.

Important caveat

REHABILITATION IS THE DOMINANT INTERVENTION. PT/OT/SLP time outranks any peptide. Cerebrolysin and semax are registered prescription medicines in their approved jurisdictions — neurology + rehab team coordination is the precondition, not a peptide-clinic decision. Hemorrhagic-stroke users: most trials are ischemic-dominant; the evidence base thins substantially, and BP-discipline-tightness of post-hemorrhagic care argues for tighter neurology coordination. Post-stroke epilepsy risk (~5-10%) makes abrupt benzodiazepine discontinuation dangerous; Selank-as-taper-adjunct is psychiatrist-managed, never self-directed.

Peptides editorially relevant to stroke recovery

4 peptides from the library — each evidence-tiered honestly.

Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.